COVAX announces new agreement, plans for first deliveries
COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income level, today announced the signing of an advance purchase agreement with Pfizer for up to 40 million doses of the Pfizer-BioNTech vaccine candidate, which has already received WHO emergency use listing. Rollout will commence with the successful negotiation and execution of supply agreements.
Read more ...
Obesity, impaired metabolic health and COVID-19
In a Nature Reviews Endocrinology article authors from the German Center for Diabetes Research (DZD) highlight the interconnection of obesity and impaired metabolic health with the severity of COVID-19. First, they provide information about the independent relationships of obesity, disproportionate fat distribution and impaired metabolic health with the severity of COVID-19.
Read more ...
COVID-19 has multiple faces
According to current studies, the COVID-19 disease which is caused by the SARS-CoV-2 coronavirus comprises at least five different variants. These differ in how the immune system responds to the infection. Researchers from the German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn, together with other experts from Germany, Greece and the Netherlands, present these findings in the scientific journal "Genome Medicine".
Read more ...
Metformin use reduces risk of death for patients with COVID-19 and diabetes
Use of the diabetes drug metformin - before a diagnosis of COVID-19 - is associated with a threefold decrease in mortality in COVID-19 patients with Type 2 diabetes, according to a racially diverse study at the University of Alabama at Birmingham. Diabetes is a significant comorbidity for COVID-19.
Read more ...
New findings help explain how COVID-19 overpowers the immune system
Seeking to understand why COVID-19 is able to suppress the body's immune response, new research from the USC Leonard Davis School of Gerontology suggests that mitochondria are one of the first lines of defense against COVID-19 and identifies key differences in how SARS-CoV-2, the virus that causes COVID-19, interacts with mitochondrial genes when compared to other viruses.
Read more ...
How SARS-CoV-2 interacts with cells
SARS-CoV-2 infections pose a global threat to human health and a formidable research challenge. One of the most urgent tasks is to gain a detailed understanding of the molecular interactions between the virus and the cells it infects. It must also be clarified, whether these interactions favour the multiplication of the virus or - on the contrary - activate defence mechanisms.
Read more ...
Neutralizing antibodies protect against severe COVID-19
Understanding the body's immune response to SARS-CoV-2, the virus that causes COVID-19, is key to developing effective treatments and long-lasting vaccines. Of particular interest are neutralizing antibodies, which can block the virus from entering and infecting human cells, helping the immune system clear the virus and prevent future infections.
Read more ...